These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 8207045

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance.
    Stein U, Walther W, Shoemaker RH.
    Br J Cancer; 1996 Nov; 74(9):1384-91. PubMed ID: 8912533
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody.
    Fogler WE, Pearson JW, Volker K, Ariyoshi K, Watabe H, Riggs CW, Wiltrout RH, Longo DL.
    J Natl Cancer Inst; 1995 Jan 18; 87(2):94-104. PubMed ID: 7707396
    [Abstract] [Full Text] [Related]

  • 6. Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line.
    Baas F, Jongsma AP, Broxterman HJ, Arceci RJ, Housman D, Scheffer GL, Riethorst A, van Groenigen M, Nieuwint AW, Joenje H.
    Cancer Res; 1990 Sep 01; 50(17):5392-8. PubMed ID: 1974823
    [Abstract] [Full Text] [Related]

  • 7. Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease.
    Rybak SM, Pearson JW, Fogler WE, Volker K, Spence SE, Newton DL, Mikulski SM, Ardelt W, Riggs CW, Kung HF, Longo DL.
    J Natl Cancer Inst; 1996 Jun 05; 88(11):747-53. PubMed ID: 8637029
    [Abstract] [Full Text] [Related]

  • 8. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
    Sokoloff MH, Tso CL, Kaboo R, Taneja S, Pang S, deKernion JB, Belldegrun AS.
    Cancer; 1996 May 01; 77(9):1862-72. PubMed ID: 8646686
    [Abstract] [Full Text] [Related]

  • 9. Specific reversal of MDR1/P-gp-dependent multidrug resistance by RNA interference in colon cancer cells.
    Xia Z, Zhu Z, Zhang L, Royal C, Liu Z, Chen Q, Adam BL.
    Oncol Rep; 2008 Dec 01; 20(6):1433-9. PubMed ID: 19020725
    [Abstract] [Full Text] [Related]

  • 10. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
    Ramachandran C, Wellham LL.
    Anticancer Res; 2003 Dec 01; 23(3B):2681-90. PubMed ID: 12894558
    [Abstract] [Full Text] [Related]

  • 11. Pleiotropic-resistant phenotype is a multifactorial phenomenon in human colon carcinoma cell lines.
    Toffoli G, Viel A, Tumiotto L, Biscontin G, Rossi C, Boiocchi M.
    Br J Cancer; 1991 Jan 01; 63(1):51-6. PubMed ID: 1671208
    [Abstract] [Full Text] [Related]

  • 12. Variable effects of sodium butyrate on the expression and function of the MDR1 (P-glycoprotein) gene in colon carcinoma cell lines.
    Frommel TO, Coon JS, Tsuruo T, Roninson IB.
    Int J Cancer; 1993 Sep 09; 55(2):297-302. PubMed ID: 8103760
    [Abstract] [Full Text] [Related]

  • 13. Sensitivity of drug-resistant human ovarian tumor cell lines to combined effects of tumor necrosis factor (TNF-alpha) and doxorubicin: failure of the combination to modulate the MDR phenotype.
    Safrit JT, Berek JS, Bonavida B.
    Gynecol Oncol; 1993 Feb 09; 48(2):214-20. PubMed ID: 8428693
    [Abstract] [Full Text] [Related]

  • 14. Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells.
    Eijdems EW, Zaman GJ, de Haas M, Versantvoort CH, Flens MJ, Scheper RJ, Kamst E, Borst P, Baas F.
    Br J Cancer; 1995 Aug 09; 72(2):298-306. PubMed ID: 7640209
    [Abstract] [Full Text] [Related]

  • 15. MDR1 gene expression: its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines.
    Park JG, Lee SK, Hong IG, Kim HS, Lim KH, Choe KJ, Kim WH, Kim YI, Tsuruo T, Gottesman MM.
    J Natl Cancer Inst; 1994 May 04; 86(9):700-5. PubMed ID: 7908989
    [Abstract] [Full Text] [Related]

  • 16. Use of the human MDR1 promoter for heat-inducible expression of therapeutic genes.
    Walther W, Stein U, Schlag PM.
    Int J Cancer; 2002 Mar 10; 98(2):291-6. PubMed ID: 11857422
    [Abstract] [Full Text] [Related]

  • 17. Impairment of Fas-antigen expression in adriamycin-resistant but not TNF-resistant MCF7 tumor cells.
    Cai Z, Stancou R, Körner M, Chouaib S.
    Int J Cancer; 1996 Nov 15; 68(4):535-46. PubMed ID: 8945627
    [Abstract] [Full Text] [Related]

  • 18. Resistance to TNF-alpha and adriamycin in the human breast cancer MCF-7 cell line: relationship to MDR1, MnSOD, and TNF gene expression.
    Zyad A, Bénard J, Tursz T, Clarke R, Chouaib S.
    Cancer Res; 1994 Feb 01; 54(3):825-31. PubMed ID: 7905787
    [Abstract] [Full Text] [Related]

  • 19. Rapid recovery of a functional MDR phenotype caused by MRP after a transient exposure to MDR drugs in a revertant human lung cancer cell line.
    Gonzalez Manzano R, Versanvoort C, Wright K, Twentyman PR.
    Eur J Cancer; 1996 Nov 01; 32A(12):2136-41. PubMed ID: 9014757
    [Abstract] [Full Text] [Related]

  • 20. Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas.
    Hoffmann J, Schmidt-Peter P, Hänsch W, Naundorf H, Bunge A, Becker M, Fichtner I.
    Clin Cancer Res; 1999 Aug 01; 5(8):2198-204. PubMed ID: 10473106
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.